A 2008 study published by the Indian Journal of Pharm Sci investigated the role of three anti-inflammatory proteolytic enzymes and their interactions with aspirin in albino rats.
The study proves that serrapeptase possesses significant anti-inflammatory properties when taken alone and synergistically when taken with aspirin (without an increased risk of gastrointestinal ulceration). This comes as a major breakthrough in options for treating both chronic and acute inflammatory conditions. Especially with the risk of regular NSAID use, serrapeptase may be a great alternative to conventional medicines that pose risks and side-effects to the consumer.
Albino rats were used as models of inflammation after being injected with carrageenan on the hind paw. Carrageenan is a gelatinous extract from seaweed which stimulated sub-acute inflammation after the implantation of cotton pellets under the skin.
The rats were given aspirin and proteolytic enzymes separately in three different doses. Each proteolytic enzyme was observed as an enzyme-aspririn combination, with saline as the control. Administration of the anti-inflammatory treatments were given 30 minutes prior to induced inflammation and then once daily for 10 ten days thereafter.
When assessing the level of edema produced by the carrageenan-induced granulomas, serrapeptase showed better anti-inflammatory activity than the other proteolytic enzymes and aspirin.
After ten days, the cotton pellet was removed and weighed in order to observe each enzyme’s proteolytic activity. Serrapeptase was found to be more effective at reducing mass size than trypsin, chymotrypsin and aspirin in the sub-acute model of inflammation.
After administration of the enzymes and aspirin, the stomach was inspected for ulcers. The rats treated with enzymes showed a significant reduction in gastrointestinal damage compared to controls.
The findings confirm that systemic enzymes like serrapeptase are a useful option in treating and preventing inflammatory conditions.